A Night with Treehouse Networking.
Last night we went to our very first Treehouse Networking event! And, WOW it was ah-MAY-zing! We knew when we met Wesley Hoffman of Treehouse, that he was up to great things. We are so happy we were able to participate in #OpenTreeHouse at the Boo Cat Club! We ended up making a bunch of coasters from our unique Sandwich Stock paper to give away and allowed our booth visitors to round the corners of the coasters themselves. They really loved it! Cat and Christa showed off a whole bunch of print samples, and Greg even got interviewed by the Treehouse guys about The Done Dept. It was quite a success in such a beautiful space! Thanks to everyone for coming out!


The new album from conductor and Baroque violist Simon Murphy and his award-winning Baroque orchestra from The Hague, The New Dutch Academy (NDA), is a celebration of the variety, vibrancy and vitality of the European Baroque.
With Grand Tour - Baroque Road Trip, Murphy takes audiences on an exciting musical journey across Baroque Europe, meeting legendary musical personalities in the glittering musical centres of the time - from Bach in Leipzig to Handel in London, from Vivaldi in Venice to Van Wassenaer in The Hague.
"Thrilling ... an unforgettable musical journey ... infectious energy ... outstanding playing" are just some of the responses from the international music press since the album release in May 2017.
The disc is Murphy and the NDA's 6th album for Dutch quality label PENTATONE. The September 2017 official album launch concert in Amsterdam's The Concertgebouw was an all-round success. Murphy and the orchestra will continue to tour the album throughout Europe and around the world in the coming years.
Check out the album teaser here!
Album highlights include Murphy performing Telemann's classic Viola Concerto in G, Swedish lute virtuoso Karl Nyhlin in Vivaldi's sparkling Lute Concerto in D and German recorder star Elisabeth Champollion in Vivaldi's dazzling Flautino Concerto in C. Greek mega-diva, soprano Myrsini Margariti, sings a selection of Handel bravura coloratura arias including the spectacular "Brilla nell'alma".
"Sumptuous, vibrant, energetic and wonderfully secure playing"
Watch the album teaser here!


text:
package mota.dev.happytesting.useCases;

import android.widget.Toast;

import org.json.JSONArray;
import org.json.JSONObject;

import java.util.List;

import io.reactivex.Observable;
import io.reactivex.Observer;
import io.reactivex.android.schedulers.AndroidSchedulers;
import io.reactivex.annotations.NonNull;
import io.reactivex.functions.Consumer;
import mota.dev.happytesting.managers.RequestManager;
import mota.dev.happytesting.models.Image;
import mota.dev.happytesting.models.Observation;
import mota.dev.happytesting.repositories.implementations.ImageLocalImplementation;
import mota.dev.happytesting.utils.RxHelper;

/**
 * Created by Slaush on 08/07/2017.
 */

public class RemoveImages {
    private static RemoveImages instance;

    private RemoveImages() {
    }

    public static RemoveImages getInstance() {
        if (instance == null)
            instance = new RemoveImages();
        return instance;
    }

    public Observable<Boolean> removeImages(final List<Image> images, final Observation o) {
        return new Observable<Boolean>() {
            @Override
            protected void subscribeActual(Observer<? super Boolean> observer) {
                if (o.getId() != 1)
                    removeImagesOnRemote(images, o, observer);
                else
                    removeImagesOnLocal(images, o, observer);
            }
        };
    }

    private void removeImagesOnLocal(List<Image> images, Observation o, final Observer<? super Boolean> observer) {
        ImageLocalImplementation.getInstance()
                .deleteObservationImages(images, o.getLocalId())
                .subscribe(new Consumer<Boolean>() {
                    @Override
                    public void accept(@NonNull Boolean result) throws Exception {
                        RxHelper.nextAndComplete(observer, result);
                    }
                });
    }

    private void removeImagesOnRemote(final List<Image> images,
                                      final Observation o,
                                      final Observer<? super Boolean> observer)
    {
        JSONArray array = new JSONArray();
        JSONObject jsn = new JSONObject();
        for (Image i : images)
            array.put(i.getId());
        try {
            jsn.put("observacion", o.getId());
            jsn.put("images", array);
        } catch (Exception e) {

        }

        RequestManager.getInstance().deleteImages(jsn).subscribe(
                new Consumer<JSONObject>() {
                    @Override
                    public void accept(@NonNull JSONObject jsonObject) throws Exception {
                        if (jsonObject.optBoolean("success"))
                            removeImagesOnLocal(images, o, observer);
                        else
                            RxHelper.nextAndComplete(observer, false);

                    }
                },
                RxHelper.getErrorThrowable(observer, false));
    }
}

redpajama_set_name: RedPajamaGithub


text:
Q: How to add a column in result set and set values in that field? I have two tables
people
name    id

man1    456
man2    123
man3    789

notes
content id

testing 123
hello   456

I have two queries that select records from the table people if a note for that person exists.
SELECT * FROM PEOPLE WHERE ID IN (SELECT ID FROM NOTES)
name    id

man1    456
man2    123

And
SELECT * FROM PEOPLE WHERE ID NOT IN (SELECT ID FROM NOTES)
name    id

man3    789

I would like to create a column in the result set (not in the actual table) and set the value of the field based on whether a note exists.
name    id  does_note_exist

man1    456 yes
man2    123 yes
man3    789 no

What is the appropriate syntax to do this?  Something like this would be what I'm looking for:
IF ID IN (SELECT ID FROM NOTES)
   does_note_exist = yes

IF ID NOT IN (SELECT ID FROM NOTES)
   does_note_exist = no

A: You need a LEFT OUTER JOIN:
SELECT
    p.id,
    p.name,
    CASE WHEN n.id IS NULL THEN 'no' ELSE 'yes' END AS does_note_exist
FROM people p
LEFT OUTER JOIN notes n
ON n.id = p.id
GROUP BY n.id

A: There are a bunch of ways you might do that - I think I would use a case statement:
http://dev.mysql.com/doc/refman/5.0/en/case-statement.html

redpajama_set_name: RedPajamaStackExchange


text:
Novartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts
Study discontinued due to feasibility of recruitment; no safety issues have been reported or efficacy conclusions made
Novartis remains committed to ongoing research and development for COVID-19
Supply of hydroxychloroquine (HCQ) from Novartis will continue for clinical trials and upon government requests worldwide
Basel, June 19, 2020 — Novartis has made the decision to stop and discontinue its sponsored HCQ clinical trial for COVID-19 due to acute enrollment challenges that have made trial completion infeasible. The recruitment challenge facing our HCQ trial has made it unlikely that the clinical team will be able to collect meaningful data in a reasonable timeframe to determine the effectiveness of HCQ in treating patients with COVID-19. No safety issues have been reported, and there are no conclusions on efficacy from the study.
Novartis will continue to provide supply of HCQ for ongoing investigator-initiated trials (IITs) and upon government requests, as appropriate, where certain conditions are met and the medicine is used in accordance with a nationally endorsed treatment protocol. Researchers at Novartis continue to monitor ongoing guidance from health authorities on the further study of HCQ for COVID-19, as well as the decision by the US Food and Drug Administration to stop the emergency use authorization of HCQ for COVID-19 treatment. In addition, ongoing studies involving other Novartis treatments continue, as well as the newly announced support of a potential vaccine. Novartis also continues to collaborate to find answers for COVID-19 through various partnerships with multi-stakeholder external consortia.
Novartis wishes to thank all of the patients, their families, investigators and healthcare professionals who played a vital part in our HCQ clinical trial (CJWT629A12301, NCT04358081) for COVID-19.
More information about the Novartis response to COVID-19 is available on novartis.com/coronavirus.
This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "seek," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products, or regarding our activities and commitments to respond to the COVID-19 pandemic. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that such products will be commercially successful in the future. Nor can there be any guarantee that our activities and commitments to respond to the COVID-19 pandemic will achieve any or all of their intended goals in the expected time frame, or at all. In particular, our expectations regarding such products, activities and commitments could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.
Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world. Find out more at
https://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact [email protected]
Novartis Media Relations
Anja von Treskow
Novartis Global Media Relations
+41 61 324 2279 (direct)
+41 79 392 8697 (mobile)
Eric Althoff
Novartis US External Communications
[email protected] Ryan McBride
Novartis Global Drug Development Communications & Advocacy
+41 61 324 12 88 (direct)
+41 79 156 92 97 (mobile)
Steffen Kurzawa
Sandoz Communications
+49 80244-762590 (direct)
+49 170 901 2622 (mobile)
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
Central North America
Samir Shah +41 61 324 7944 Sloan Simpson +1 862 778 5052
Pierre-Michel Bringer
Thomas Hungerbuehler
Isabella Zinck +41 61 324 1065
+41 61 324 7188 Cory Twining +1 862 778 3258

redpajama_set_name: RedPajamaCommonCrawl


text:
News: Grammy Winning Casting Crowns Announces "Only Jesus" 2019 Spring Arena Tour With Zach Williams And Austin French
Home Christian News News: Grammy Winning Casting Crowns Announces "Only Jesus" 2019 Spring Arena Tour With Zach Williams And Austin French
By Abby Young | Christian News | 0 comment | 13 November, 2018 | 1
As multi-platinum selling and GRAMMY® winning group Casting Crowns prepares for this week's release of a brand new studio album, Only Jesus (Nov. 16), the group announces the Only Jesus Tour, a 37-city spring arena tour run featuring fellow Grammy winner Zach Williams and Austin French. The tour kicks off Feb. 21, in Richmond, Va., and travels to major markets in New Jersey, Massachusetts, Maine, New York, North Carolina, Pennsylvania, Indiana, Kentucky, Mississippi, Michigan, Illinois, Missouri, Georgia, Florida and more before wrapping up on May 4, in College Station, Texas.
Tickets for most cities on the Only Jesus Tour will go on sale this week, with an early pre-sale campaign beginning at 10 a.m. local time Wednesday, Nov. 14, and running through 10 p.m. on Thursday, Nov. 15. The public on-sale launch will begin at 10 a.m. local time Friday, Nov. 16. Several exclusive VIP Fan Experience packages are available featuring options such as front row or premium seating, a pre-show jam session/Q&A with Casting Crowns, group photo opportunities, merchandise, signed tour poster and more. For ticket details, visit www.CastingCrowns.com/tour.
Presented by Compassion International, the Only Jesus Tour will support Casting Crowns' brand new studio album, Only Jesus, releasing this Friday. Over the past few weeks leading up to the street date, the band has released six of the album's tracks early, including the title cut and first radio single, "Only Jesus," which is one of the fastest charting songs of 2018 and already a Top 10 smash. "Only Jesus" gives Casting Crowns their 26th Top 10 song on the Hot Christian Songs chart, the most by any group.
Casting Crowns will hit the West Coast this holiday season for the highly-anticipated It's Finally Christmas Tour with special guest Hannah Kerr. Beginning Nov. 29, in Portland, Ore., the Christmas run will hit 7 cities including Seattle, Spokane, Abbotsford (BC), Oakland and Irvine, ending Dec. 6, in San Diego.
With more than 11 million records sold, Casting Crowns has held the position of Billboard's top-selling act in Christian music since 2007. The band continues to impact audiences with their powerful live shows, having performed for nearly seven million fans and has crossed over a milestone of more than 100,000 child sponsorships generated through Casting Crowns' concerts. For more information on the Only Jesus Tour, visit www.CastingCrowns.com.
THE ONLY JESUS TOUR – SPRING 2019
Dates, markets and venues subject to change without notice.
21 — Richmond, VA — Altria Theater
22 — Newark, NJ — Prudential Center (on sale now)
23 — Springfield, MA — MassMutual Center
24 — Bangor, ME — Cross Insurance Center
26 — Lowell, MA — Lowell Memorial Auditorium
28 — Binghamton, NY — Floyd L. Maines Veterans Memorial Arena
01 — Salem, VA — Salem Civic Center
02 — Concord, NC — Cabarrus Arena
07 — Fort Wayne, IN — Memorial Coliseum
08 — Getzville, NY — The Chapel at CrossPoint|
09 — Pittsburgh, PA — PPG Paints Arena
14 — Evansville, IN — Ford Center
15 — Johnson City, TN — Freedom Hall
16 — Corbin, KY — Corbin Arena
17 — Hershey, PA — Giant Center (on sale 11/30)
21 — Independence, MO — Silverstein Eye Centers Arena (on sale 12/21)
22 — Tupelo, MS — BancorpSouth Arena
23 — Jackson, MS — Mississippi Coliseum
28 — Pensacola, FL — Pensacola Bay Center
29 — Woodstock, GA — First Baptist Church Woodstock
30 — Jacksonville, FL — Daily's Place Amphitheater
04 — Gape Girardeau, MO — Show Me Center (on sale 12/7)
05 — Charleston, WV — Charleston Civic Center
06 — Indianapolis, IN — Bankers Life Fieldhouse (on sale 11/30)
09 — Rockford, IL — BMO Harris Bank Center
11 — Fargo, ND — FARGODOME (on sale 12/7)
12 — Minneapolis, MN — Target Center (on sale 12/7)
13 — Cedar Rapids, IA — US Cellular Center (on sale 12/7)
14 — Sioux Falls, SD — Denny Sanford Premier Center (on sale 12/7)
18 — Greenville, SC — Bon Secours Wellness Arena
19 — Raleigh, NC — PNC Arena
25 — Grand Rapids, MI — Van Andel Arena (on sale 12/14)
26 — South Barrington, IL — Willow Creek Community Church (on sale 11/30)
27 — St. Charles, MO — The Family Arena (on sale 2/12)
02 — Cedar Park, TX — H-E-B Center at Cedar Park
03 — Hidalgo, TX — State Farm Arena
04 — College Station, TX — Reed Arena – Texas A&M University (on sale 1/18)
ABOUT CASTING CROWNS
Prolific CCM band Casting Crowns has achieved sales milestones with more than 11 million albums sold including one RIAA 2x multi-Platinum album, five RIAA Platinum albums, two RIAA Platinum DVDs, seven RIAA Gold albums, four Gold DVDs, one RIAA Platinum certified single and five RIAA Gold certified digital singles. The band currently holds the position as Billboard's top-selling act in Christian music since 2007. Casting Crowns has also been honored with four American Music Awards (out of seven total nominations), a GRAMMY Award for its 2005 album Lifesong, and seven GRAMMY nominations. In addition, the group has garnered 18 GMA Dove Awards and two Billboard Music Awards from 11 total Billboard Music Award nominations. Casting Crowns' seven band members all remain active in student ministry in the Atlanta area and tour according to their local church commitments. Serving his 25 plus years in youth ministry, lead singer/songwriter Mark Hall maintains his role as the student pastor at Eagle's Landing First Baptist Church in Atlanta. For more information, visit www.castingcrowns.com.
ABOUT ZACH WILLIAMS
As a husband, father, singer, recording artist, songwriter and worship leader, GRAMMY® winner (Best Contemporary Christian Album, Chain Breaker) and multi-GMA Dove Awards winner (Artist of the Year and New Artist of the Year) Zach Williams continues to make history. Achieving two consecutive radio No. 1 hits for 35 weeks as a debut artist ("Chain Breaker," "Old Church Choir") Williams' music comes from a place of humility and honesty as his songs are a direct reflection of God's redemption in his life. "Chain Breaker," his official RIAA-certified gold record-breaking single, has impacted millions of people around the world, earning Williams his first GRAMMY® nomination (Best Contemporary Christian Music Performance/Song, 2017) and a Billboard Music Award nomination (Top Christian Song). He's also won two GMA Dove Awards (New Artist; Pop/Contemporary Recorded Song of the Year, "Chain Breaker") and a K-LOVE Fan Award (for Breakout Single). Williams was also named Billboard's 2017 Top Christian Male Vocalist and New Artist of the Year. Apple Music chose him as Artist of the Week in December 2016, while "Chain Breaker" was the top track of 2016 on iTunes' Christian Songs chart and also reached No. 12 on Billboard's Hot Rock Songs chart. Williams has also been awarded by BMI with a Citation of Achievement for "Chain Breaker," recognizing the song for its national popularity and reach. For more information, please visit www.ZachWilliamsMusic.com.
ABOUT AUSTIN FRENCH
Growing up in small town, Cordele, Ga., Austin French dreamed of sharing his faith and passion for Jesus through music at a young age. Being surrounded by a musical family inspired his passion for writing music. As he began to develop his gifts he formed bands learning to take his music to stages and churches. After becoming the worship pastor at Journey Church, in Tifton, Ga., French met his wife, Joscelyn. While serving there, French was featured on the first season of the ABC TV show "Rising Star," where he finished as runner-up. After the show, Austin and his wife moved to Florida, and then to Nashville, Tenn., in 2017 where French began his journey into the CCM industry, signing with Fair Trade Services. After moving to Nashville, French and his wife adopted their son, and while in the process, gave birth to their second little boy. French's debut album, Wide Open is available now. For more information, visit www.austinfrenchmusic.com.
ABOUT COMPASSION INTERNATIONAL
Founded in 1952, Compassion International is a Christian child development organization that works to release children from poverty in Jesus' name. Compassion revolutionized the fight against global poverty by working exclusively with the Church to lift children out of spiritual, economic, social and physical poverty. Compassion partners with more than 6,700 churches in 25 countries to deliver its holistic child development program to over 1.8 million babies, children and young adults. It is the only child sponsorship program to be validated through independent, empirical research. For more information, visit www.compassion.com.
Austin French, Casting Crowns, Compassion International, Only Jesus Tour, Zach Williams
8 Must See Winter/Spring Tours
By Free CCM | 0 comment
Looking for great shows to see in the next few months? This is our list of the the top 8 tours that you will not want to miss this Winter and Spring! Casting Crowns "Only
News: Casting Crowns Announces "Only Jesus" Fall Tour With Kari Jobe, Cody Carnes, Jamie Kimmett, Zauntee
GRAMMY® winning multi-platinum group Casting Crowns has announced plans to extend its widely popular Only Jesus Tour this fall, following a successful 37-city spring run which included multiple sell-outs in arenas across the country. The
The Top Christian Songs For Mom
Holy Spirit – Francesca Battistelli Stand In You Love (Live) – GATEWAY
News: MercyMe And TobyMac Top 2018 K-LOVE Fan Awards' Nominations With Four Nods Each
Multi-platinum selling artists MercyMeand TobyMac have garnered the most nominations for this year's K-LOVE Fan Awards including four nods total in the major categories of Artist of the Year, Male Artist of the Year, Group
News: Casting Crowns Extends "The Very Next Thing" Fall Tour with Special Guest Zach Williams
Multi-platinum selling and GRAMMY® winning group Casting Crowns will hit the road again this fall to extend its hugely successful "The Very Next Thing" Tour, featuring special guest Grammy-nominated artist Zach Williams. "The Very Next


>> next, look at the status of use north korea diplomacy after president trump canceled the sum and singapore that was scheduled to take place on june 12. 12th. from the stimson center in washington, d.c. this is about an hour. >> i think we're going to get it started because this is going to be just an hour. welcome everyone. my name is yuki tatsumi. i'm the program director hat stimson center and we're delighted to have these were very interesting speakers to chat with us a little bit about what is beyond the trump kim summit. when i first give the title beyond trump kim summit, and please imagine the heart attack of me seeing that news that someone pulled -- showing of now seem to be back on. we are basically getting whiplash moment every day on this one with the sum is going to be on, off, on, off. so who knows what happens when next week comes? in light of that uncertainty we are delighted to have yun sun and katsu furukawa. and jenny town from 38 n. which now now proud to say that a part of stimson center family. and my other codirector, my better half of the program, yun sun.


text:
Get in your zone as a Gallagher Chiefs member
Grab your 2020 Membership
Ever wondered what it's like being a loyal Gallagher Chiefs member? Here's all you need to know on what you can expect if you join our tribe with a 2020 Membership!
Whatever your seating preference, grandstand preference or budget there is an option for you. We have eight different zones to suit everyone's needs, from covered seating to a prime spot behind the goal-line or a place to bring the kids.
Prices start from $120 per adult and $48 per child, which will cover all seven home games at FMG Stadium, Waikato plus loads of exclusive member's benefits (Link this text to members page). However free kids' memberships are available with every adult membership purchased in fan, family uncovered and green zones.
Red Zone Members (Brian Perry Stand):
These are the premium seats at FMG Stadium Waikato. Enjoy covered seats at the top of the Brian Perry stand with an expansive view of the playing field, never missing a moment no matter where the action takes place. Access the stadium through gate 3 or 4 and have easy access to a range of facilities including bars, a merchandise shop, coffee carts, food and beverage outlets and toilets in the covered The Brian Perry Stand has everything you need for an amazing match day experience. Membership prices from $365.
Black Zone Members (Brian Perry Stand):
You'll be closer to the action in the uncovered seats of the Black Zone. It is the closest zone to the tunnel in which players enter and exit the field so perfect to feel a part of the run-out spectacles and dugouts. Access the stadium through gate 3 or 4 and have easy access to a range of facilities including bars, a merchandise shop, coffee carts, food and beverage outlets and toilets in the covered concourse. Black Zone Membership prices from $220 (adults) $48 (children)
Yellow Zone Members (WEL Network Stand)
Enjoy covered seats at the top of the Wel Network stand, the jewel of Mill Street side. With an expansive view of the playing field, you'll never miss a big play no matter where the game goes. Access the stadium through gate 1 or 2 and have easy access to a range of facilities including bars, a merchandise shop, the primary 1-day kids Fun Zone, coffee carts, food and beverage outlets and toilets around the back of the Wel Network Stand. Prices from $310 (adults) $48 (children)
Fan Zone Members (WEL Network Stand)
Get closer to the on-field action in uncovered seats in the Wel Network stand. You'll be in prime position to experience the flame pot features, big screen and Maori Toa entrance. Access the stadium through gate 1 or 2 and have easy access to a range of facilities including bars, a merchandise shop, the primary 1-day kids Fun Zone, coffee carts, food and beverage outlets and toilets around the back of the Wel Network Stand. Prices from $180 (adults) $48 (children) or free with an adult membership
Family Zone Covered Members (WEL Network Stand)
Members in this zone will enjoy covered seats at the top left of the Wel Network stand. With an expansive view of the playing field this is perfect for families who are after stellar views of the game. Family Zones are alcohol-free zones. Access the stadium through gate 2 and have easy access to a range of facilities including bars, a merchandise shop, the primary 1-day kids Fun Zone, coffee carts, food and beverage outlets and toilets around the back of the Wel Network Stand. Prices from $240 (adults) $180 (students) $48 (children)
Family Zone Uncovered Members (WEL Network Stand)
Family Zone Uncovered Members will be closer to the action in uncovered seats located at the bottom left side of the Wel Network stand. You'll be super close to the 1-Day Fun Zone so the young ones will have an easy stroll to pick up their free kids' packs. Family Zone Uncovered is also alcohol-free. Access the stadium through gate 2 and have easy access to a range of facilities including bars, a merchandise shop, the primary 1-day kids Fun Zone, coffee carts, food and beverage outlets and toilets around the back of the Wel Network Stand. Prices from $145 (adults) $115 (students) $48 (children) or free with an adult membership.
Goal Line Members (Goal Line)
Enjoy uncovered seats at the north end of FMG Stadium Waikato. With an 'up the field' view you'll be in a nice position to catch kicks at goal, get a close view of the players warming up and be the closest to any tries scored down your end. Goal Line Zone is accessed through gate 4 and has easy access to a range of facilities in the Brian Perry Stand including bars, a merchandise shop, coffee carts, food and beverage outlets and toilets. Prices from $150 (adult) $48 (children) or free with adult membership.
Green Zone Members (Embankment)
Feel free to take any uncovered spot on the south-end embankment with leaning posts scattered across the various levels. With an 'up the field' view you'll also be in a good spot to catch kicks at goal, get close to the players warming up and be right there for any tries scored down your end. Green Zone is easily accessed through either Gate 2 or 3 and you'll have access to a beverage tent and food trucks at the top of the embankment. Prices from $120 (adults) $60 (students) $48 (children) or free with an adult membership.
The Gallagher Chiefs first home game is this Saturday against the Crusaders at FMG Stadium Waikato on 8 February at 7.05pm
2020 Gallagher Chiefs memberships are on sale here: https://www.chiefs.co.nz/2020-memberships


text:
QuickList: November inflation rates for Canadian provinces, territories
OTTAWA – Canada's national inflation rate was 0.9 per cent in November, Statistics Canada says. Here's what happened in the provinces and territories. (Previous month in brackets):
— Newfoundland and Labrador 2.2 (1.5)
— Prince Edward Island 2.6 (2.0)
— Nova Scotia 1.0 (0.9)
— New Brunswick 1.2 (0.8)
— Quebec 0.6 (0.2)
— Ontario 1.1 (0.9)
— Manitoba 2.4 (2.2)
— Saskatchewan 1.4 (1.5)
— Alberta 1.7 (1.0)
— British Columbia -0.2 (-0.3)
— Whitehorse, Yukon 1.2 (1.6)
— Yellowknife, N.W.T., 1.4 (1.6)
— Iqaluit, Nunavut 0.7 (1.7)


text:
Q: Adding a css class to knockout without breaking the default code I'm trying to add a css class in the field.html that is used on checkout.
My code:

Now it does add the 'hideBusiness' class but the default class '_required' gets removed from the field. I'm not sure why that is?
This is the output:

~~ other code ~~

Without my code it outputs:

~~ other code ~~

I feel like it might have to do with the double css binding but i'm not sure how to combine them?

A: You should just add your class "hideBusiness" to additionalClasses prop on the uicomponent , you can use whatever logic for this and you don't have to edit the template at all


Great news! Our Q4 RT training session will be held in Los Angeles, CA on November 4-5, 2014! We do have a limit on how many people we can effectively teach, so please register as soon as you can to make sure you get a seat. If you can't make LA, please feel free to suggest a future location by dropping us a line at training@bestpractical.com! Also, we still have a few spots in our upcoming Boston training! If you haven't registered yet but want to attend, now is the time!
This training will introduce you to the new features in RT 4.2 as part of a comprehensive overview of RT. Whether you're an old hand at RT or a recent convert, you'll have a good understanding of all of RT's features and functionality by the end of the session.
The first day starts off with a tour of RT's web interface and continues with a detailed exploration and explanation of RT's functionality, aimed at non-programmer RT administrators. We'll walk through setting up a common helpdesk configuration, from rights management, constructing workflows and notifications, and the basics of Lifecycles.
The second day of training picks up with server-side RT administration and dives into what you need to safely customize and extend RT. We'll cover upgrading and deploying RT, database tuning, advanced Lifecycle configurations, writing tools with RT's API, building an extension, and demonstrate how to extensibly alter the web UI and internal functions.
It goes without saying that you'll get the most out of training if you attend both days of the course, but we've designed the material so that you can step out after the first day with a dramatically improved understanding of how to use RT.
For both days, the cost is USD $1,495. A single day is USD $995. Each class includes training materials, a continental breakfast, and snacks (lunch is not provided).
If you'd like to pay with Visa, MasterCard or Discover, please visit Best Practical's online store. Unfortunately we are unable to accept American Express or PayPal. If you'd prefer to pay with a purchase order, please email us at training@bestpractical.com. Be sure to include: if you want to attend both days or a single day and the full names and email addresses of attendees.
Finally, please contact us at training@bestpractical.com for discounted pricing if you are from an academic institution or if you'd like to send more than 3 people.
Join us for our Q2 Request Tracker training in Dallas!
Hello! Best Practical is pleased to announce our second Request Tracker training for 2014! We will be in Dallas, Texas on May 20-21. We do have a limit on how many people we can effectively teach, so please register as soon as you can to make sure you get a seat. If you can't make Dallas, we will have upcoming sessions later this year in Boston, MA and Los Angeles, CA. Please let us know if you have a suggestion for a future location by dropping us a line at training@bestpractical.com!
Please contact us at training@bestpractical.com for discounted pricing if you are from an academic institution or if you'd like to send more than 3 people.
Thanks for your support of Request Tracker!
Don't miss Best Practical's first Request Tracker training of 2014 in London!
Just a reminder that Best Practical's first RT training is taking place on March 19-20 in London, UK. This will likely be our only non-US public session this year. This training will introduce you to the new features in RT 4.2 as part of a comprehensive overview of RT. Whether you've been using Request Tracker for years or are a recent convert, you'll have a good understanding of all of RT's features and functionality by the end of the session.
For both days, it is USD $1,495 for one person. This includes training materials, continental style breakfast, and snacks. You can register by heading over to our shop to pay via credit card (Amex not accepted, unfortunately.) You can also drop us a note at training@bestpractical.com if you'd rather we send an invoice. Finally, if you're from an academic institution, or would like to send more than 3 people, let us know so we can give you a bit of a discount. We're always happy to answer any questions, so please don't be shy.
In RT 4.2 we've updated the scrips configuration pages and the changes will save RT admins a bunch of time when managing scrips. Specifically, you can now apply scrips globally or to selected queues on one simple configuration page.
RT's global scrips work for most notifications, often with just some updates to the global templates. If you want different templates for specific queues, you can create a queue-specific template with the same name as the global template and the global scrip will use that template for notifications on that queue.
But what if you want to disable a notification for just one queue and leave it on for all the others? In previous versions of RT, this meant disabling the global scrip, then creating a new scrip in each queue that still needed it. In RT 4.2, this is now much easier.
For example, let's assume we have an Office queue for internal office requests and everyone agrees we don't need to see the 'On Resolve' notification when the new staples have come in. First we go to Admin > Global > Scrips and click on the "On Resolve Notify Requestors" scrip.
On the Basics page you'll notice a new Applies to label showing "Global" and a check box to enable and disable the scrip. You could previously disable scrips in a dropdown menu in the same location, but the other items in the dropdown were the scrip stages, so users often didn't know the Disabled option was in there.
The current options are fine for our case, so we click on the Applies to link in the submenu. The resulting page says "Applies to all objects", meaning the scrip is currently global. Below that is a checkbox you can check to remove the scrip from all objects. We check that and click Submit to see the new Modify page.
The new page displays all of our queues with checkboxes so we can check all queues but the Office queue. You can also change the scrip stage (normal or batch) or change the template at this point.
After we submit, we see the scrip has been applied to the selected queues.
You can now easily move scrips between queues or make it global again.
From the scrip listing pages, at both the global and queue level, you can now also manage the order in which scrips run. For default configurations, this isn't an issue for most notifications, but as you add more scrips you sometimes want to guarantee that one scrip will run before another for the same sort of update (comment, correspond, etc.). To change the order, just click the Up and Down links on the right.
You'll also notice we now separate regular scrips and batch scrips to make the running order more clear. Batch scrips run at the end of a transaction after all other scrips have run.
Scrips that are not applied appear at the bottom of the screen and you can easily select and apply them either globally, if you're on the global modify page, or on the current queue if you're on a queue-specific scrip page.
These updates should make it much easier to reuse scrips across a portion of the queues in your system and selectively apply them. The new scrip display and ordering features should also make it easier to view and control when they run.
If you'd like to learn about more new features in 4.2, take a look at the new feature overview.
In RT 4.2 we've added some new configuration options that allow you to cleanly organize your custom fields, improving the look of pages and making it easier to view and update custom field data.
The first entry under RT::Ticket will create a new "Product Details" grouping and include the three custom fields listed. You can add more entries and custom fields to set up as many new groups as you need. If you have additional custom fields not assigned to a group, they will appear in the standard Custom Fields portlet as usual.
The ticket groupings appear on the ticket create, display, and update pages. The ordering of the custom fields in each group is still controlled by the queue configuration. You can find this by going to Admin > Queues, clicking on a queue, then selecting Custom Fields > Tickets in the submenu. Just click Up/Down on the configuration page to change the ordering.
The custom field groupings also apply to RT's self service pages. You might want your customers to set some custom fields to help with support requests, so you can give them permission to see and edit selected custom fields even though they are unprivileged users. They can then fill out some fields as part of their support request.
You can find details on the new custom field grouping features in the RT_Config documentation. We think you'll find this a nice way to bring some order to you custom fields.
If you missed some earlier posts, you can find more new RT 4.2 features in the new feature overview.


1. How can I obtain a copy of the Rowland NMR Toolkit (RNMRTK) program suite?
2. What is shared memory?
3. How do I increase the amount of shared memory on my system?
4. What special changes are needed to make RNMRTK work on an Apple OSX system?
5. Why does the script return "noisecalc: command not found"?
6. Why does the script return "Insufficient memory" when executing the rnmrtk LOAD or LOADVNMR command?
7. My section program does not support the -c and -d options. What do I do?
8. Why do I get an "Illegal size value" error when creating a shared memory section?
9. How can I setup a Varian BioPack sequence to use a sample schedule?
10. How do I invoke rnmrtk?
The Rowland NMR Toolkit program suite is made freely available to academic and not-for-profit institutions. It is asked that you fill out a license agreement which can be found here. The license agreement may be mailed to the address listed at the top of the agreement or faxed to 1-860-679-8407. Contact Jeff Hoch for further information about the Toolkit, including commercial licenses.
Shared memory, as the name implies, is system memory that may be shared between programs. The Rowland NMR Toolkit programs utilize shared memory as a "scratch pad" to store data while computations are performed. The shared memory will utilize physical memory if it is available but can also be located on the disk in a swap partition. Before running RNMRTK programs a shared memory section file needs to be created and needs to be created large enough to contain the data. The size must be large enough to hold the raw NMR data and any signal processing events which may change the data size such as zero-filling. Shared memory sections are created using the RNMRTK program section. By default unix systems have restrictions on the size of shared memory sections that may be created. In order to utilize the RNMRTK it is very likely that you will need to change the configuration files to allow larger shared memory sections to be created. See increasing the size of shared memory sections on my system for more details. Note that the RNMRTK script generator relies on a newer version of the program section which has -c (create) and -d (delete) options. If you have an older version of section which does not support these options it is strongly advised that you obtain a more current version of the software. Contact Jeff Hoch to obtain a more recent version.
The maximum size of a shared memory section is controlled by the kernel parameter shmmax. This parameter is set slightly differently depending on the operating system you are using. Below are instructions for Linux, Mac OSX 10.3 and earlier, and Mac OSX 10.4. shmmax may be changed up to a value which is equal to the total amount of memory in the system (physical + swap). Note that increasing the value of shmmax does not affect the amount of available RAM for the system and other programs. Also, once a shared memory section is created with the section program NO memory is actually used. Memory is only used once data is loaded into the shared memory section. Thus creating a shared memory section by itself will do nothing to system performance. However, once data is loaded into the shared memory section it will remain there until it is purged or the shared memory section is destroyed. Note that the script generator by default deletes all shared memory sections at the end of the script to avoid wasting memory by accidentally forgetting to delete the shared memory section after processing is complete. Data can simply be loaded into the RNMRTK program with the load command if needed after the processing is complete.
How large should you set shmmax? You want to set shmmax to a value large enough to handle any data set you may want to process with the RNMRTK. shmmax is entered in bytes. I often set shmmax equal to 1,000 or 2,000 MB on our systems, where 1 MB = 1048576 bytes. The section program, which creates the shared memory sections, creates a 1024 byte header in addition to the size stipulated when it is executed. Because of this I generally set shmmax 1 MB larger than the largest data set size I expect to process. For example if I want to set shmmax to 1 GB the value you will enter for shmmax will be equal to 1048576 x (1000 + 1) = 1049624576.
Information about the current shared memory size limitations for your system may be obtained by using the ipcs command. For linux comptuers you may use ipcs -ml. For OSX systems you may try ipcs -M.
•For Linux computers I add the following lines to the end of the /etc/sysctl.conf file and then reboot. Of course you may choose a different value for shmmax for your system.
Note: This second method will not be permanent and will need to be redone after a reboot.
•For OSX 10.3 computers I edit the following lines in the /etc/rc file and then reboot. Unlike linux computers where shmmax may be set to any value, the value of shmmax should be an integer multiple of the initial value already located in the rc file. For our systems I simply multiplied shmmax by 257 and replaced the value. You also must increase shmall by the same integer multiplier that was used for shmmax (257 in my example). Of course you may choose a different multiplier than 257 for your system.
•For OSX 10.4 computers I edit the following lines in the /etc/rc file and then reboot. Unlike linux computers where shmmax may be set to any value, the value of shmmax should be an integer multiple of the initial value already located in the rc file. For our systems I simply multiplied shmmax by 257 and replaced the value. You also must increase shmall by the same integer multiplier that was used for shmmax (257 in my example). Of course you may choose a different multiplier than 257 for your system.
# the shmmax and shmall values by 257 from their default values.
The program nosiecalc is a new addition to the RNMRTK suite and may not be located in the exe folder of rnmrtk program if you did not recently obtain a copy. The noisecalc program analyzes noise in your spectrum in order to automatically obtain initial guess for def and aim to perform a maximum entropy reconstruction. If noisecal is not in your copy of the RNMRTK you may either go to the downloads and follow the instructions for installing noisecalc, or obtain a more recent version of the RNMRTK program suite. I recommend the latter as there have been many fixes to the program besides the addition of noisecalc.
The RNMRTK script generator is setup to always create the smallest shared memory sections needed to process the data. The RNMRTK program uses 32 bit data (4 bytes) and utilizes a 1024 byte header. When the program section is used to create shared memory sections, only the size of the actual NMR data is entered. The section program automatically multiplies the total size by 4 to deal with the 32 bit data and adds 1024 bytes to take care of the header size. Older version of the section program did not do this. If you have an older version of section program which does not adjust automatically for 32 bit data and the header size you can fix the problem by manually editing the script to make the shared memory sections larger or obtain a more recent version of the RNMRTK program suite. I highly recommend the latter as many other changes to the program have been made. Another possible problem is that there was an earlier error in the script when creating a shared memory section that stated "Illegal value". In this case an existing shared memory section would exist that is too small to hold all of the data and the script encountered an error when trying to make a larger shared memory section. The most likely cause of this would be that the value of shmmax has not been set large enough on your system for the data set you are processing. See FAQ #3 for more information about this.
The scripts created with the RNMRTK script generator utilize the -c (create) and -d (delete) options of the section program. These options are new additions to the section program and may not be present on your distribution if it is older. The fix is to get the latest version of the RNMRTK program suite.
The most likely scenario for getting an "Illegal size value" error when creating a shared memory section is that the value of the kernel parameters shmmax or shmall are set too small for the memory section you are attempting to create. shmmax sets the largest single shared memory section which may be created on the system and shmall sets the maximum size of all shared memory sections combined on the system. In order to use the RNMRTK the value of shmmax and possibly shmall will need to be adjusted to a value large enough to hold the NMR data sets which you are processing. See FAQ #3 for instructions on how to do this.
Forturnatly the folks at Varian and the Orekhov group have made this very easy. Once you have a BioPack sequence loaded and setup properly it is a two step process. First you run the macro BP_NLSinit (which is installed in the latest version of BioPack). This macro creates a new pulse sequence suitable for non-uniform data collection with the same base pulse sequence name with a _S added to the end and compiles it. Creates new parameters needed to use a sample schedule, changes some parameters such as seqfil to match the new sequence, and creates a new parameter list dgnls. By entering dgnls the newly created parameters can be adjusted. To run the BP_NLSinit macro you simply type BP_NLSint(dim) from the VNMR command line, where dim is the number of dimensions in the experiment. For VNMRJ these steps are done through buttons in the Digital Filters page. However, I do not have a copy of VNMRJ yet so I can't speak for the exact method. It should be quite straightforward. The second step is to create a sample schedule and adjust parameters so that the sample schedule is used in the data collection. There are two options for this. One is to let the Varian macros generate the sampling schedule for you based on information provide in the dgnls window. The second is to create your own schedules with sampsched2d, coast, our on-line sample scheduler, or any other method you choose. To use the Varian macro method you need to set nimax and ni2max to the maximum increment size you want in each dimension. You then set ni and ni2 to some values. The product of ni and ni2 will determine the number of acquisition units (lines in the sample schedule) that are created. ni and ni2 lose their traditional meaning when using a sample schedule as both are incremented together based on the values in the sample schedule. They are only used here as a means of setting the number of lines in the sample schedule. There is one issue however, the macro is designed so that ni and ni2 must be smaller than nimax and ni2max, respectively. Once ni and ni2 are set you must set T2sp and T2sp2 which controls the decay constant which shifts the distribution of points that will be picked. The parameter SPARSE should be set to "y" and then you execute the macro BP_NLSset. This will create a sample schedule in the /vnmrsys/exp# folder with a name that is the same as the pulse sequence but has a .hdr_3 extension. If you are using your own sample schedule simply copy the schedule to the /vnmrsys/exp# folder and rename it to have the same name as the pulse sequence but with a .hdr_3 extension. Set ni=1 and ni2=the number of lines in the sample schedule. Make sure the SPARSE flag is set to "y" and you are ready to go. Just a few notes. This procedure describes a 3D case, but can be easily adapted to other dimensionality experiments. This method uses sample schedules that start at 0. The RNMRTK needs the sample schedule to start at 1. In the downloads page you may download a Perl script that can be used to adapt sample schedules by either adding or subtracting 1 from all the values.. Make sure the the SPARSE flag is set to "y" or you will collect a "normal" experiment. Also make sure that the phase and phase2 parameters are set properly (typically to phase2,phase) for 3D experiments.
10.How do I invoke rnmrtk?
In order to use the Toolkit you have to know where the programs reside on your computer. Once you know where they are located, the easiest way to use the Toolkit is to add the name of the directory they reside in to your PATH environment variable.
For example, on vp3 the Toolkit resides in /usr3/rnmrtk/rnmrtk.v3/exe. Once you have added the directory name to your PATH, you invoke the Toolkit and its ancillary tools simply by typing their names, e.g., rnmrtk.
The Toolkit needs a "scratch pad" to store the data while it carries out computations. It uses something called a shared memory section to do this. Shared memory resides in the virtual address space of the computer; if there is lots of random access memory available, it will usually reside there, but when there is not enough memory, parts of the shared memory section may by written out to the disk, in an area reserved for use by the operating system called swap space. Shared memory is just that: it can be shared by more than one program at a time. For example, you could run RNMRTK in one window, and run Seepln or Contour in another window to display the results processing by RNMRTK. It is also possible to have more than one window running RNMRTK connected to the same shared memory section; usually this is not a good idea, since it easy to get into conflicts.
Whenever RNMRTK or one of the other programs is invoked, it will tell you if there are other programs attached to the same shared memory section. One additional feature of shared memory sections is worth noting: they are not permanent -- the data they contain will not be saved unless you explicitly tell RNMRTK to save it for you. Shared memory sections are destroyed whenever the system re-boots, but otherwise they linger. They occupy system resources (memory or swap space) even when they are not being used, so it is always good etiquette to remove shared memory sections when you are finished using them.
Before creating a shared memory section, you first need to know how much space you will need. The amount is determined by the size of the spectrum you want to compute. The program used to create a shared memory section, called Section (appropriately enough) prompts you for the size of the spectrum in each dimension. You should give it large enough numbers so that the spectrum will not grow larger than the space available during the data processing steps, but no larger than necessary. For example, if you want to generate a 2048 by 4096 hypercomplex two-dimensional spectrum, you would invoke section and give respond with 2048 4096 4 to the prompt. The program multiplies the sizes of the dimensions together to determine the size of the shared memory section. Once it has created the section, it asks you if you want to remove it. If you are happy with the size, say no.
Created your NMR shared memory section.
Section size = 262145 pages.
Detached from the shared memory section.
Section is also used to remove existing shared memory sections. If you already have an active section, it will simply ask you if you want to remove it.
Found your NMR shared memory section.
Could not find shared memory section.
If you see this message you need to go back to Step 2.
4.-- Load the data, process it, and plot it!
5.-- Don't forget to remove the shared memory section when you are done!


text:
Home Virology Coronavirus NIH Launches Clinical Trial to Study Hydroxychloroquine Efficacy in COVID-19
The U.S. Centers for Disease Control and Prevention (CDC)'s National Center for Health Statistics has published a provisional figure based on available data showing a record-high of 64
NIH Launches Clinical Trial to Study Hydroxychloroquine Efficacy in COVID-19
The lack of treatment options for COVID-19 patients, potential promise in repurposing drugs, and controversy surrounding the anti-malarial drug hydroxychloroquine have created a storm of questions about the drug's efficacy that the National Institute of Allergy and Infectious Diseases (NIAID) is ready to answer. To do that, the organization is sponsoring a large randomized, controlled clinical trial to determine whether hydroxychloroquine, given in combination with the antibiotic azithromycin, can prevent hospitalization and death due to COVID-19.
The clinical trial has begun—with the first person enrolled in San Diego, CA—to evaluate the efficacy of the drugs against COVID-19. The NIAID, part of the NIH, is sponsoring the trial, which is being conducted by the NIAID-funded AIDS Clinical Trials Group (ACTG). Teva Pharmaceuticals is donating medications for the study.
"We urgently need a safe and effective treatment for COVID-19. Repurposing existing drugs is an attractive option because these medications have undergone extensive testing, allowing them to move quickly into clinical trials and accelerating their potential approval for COVID-19 treatment," said Anthony S. Fauci, MD, NIAID director. "Although there is anecdotal evidence that hydroxychloroquine and azithromycin may benefit people with COVID-19, we need solid data from a large randomized, controlled clinical trial to determine whether this experimental treatment is safe and can improve clinical outcomes."
The Phase IIb trial will enroll approximately 2,000 adults across the United States. Study participants must have confirmed infection with SARS-CoV-2, and be experiencing fever, cough, and/or shortness of breath. The investigators anticipate that many of those enrolled will be 60 years of age or older or have a comorbidity associated with developing serious complications from COVID-19, such as cardiovascular disease or diabetes. Participants will be randomly assigned to receive short-term treatment with either hydroxychloroquine and azithromycin or matching placebos. People living with HIV and pregnant and breastfeeding women also are eligible to participate in the study.
Currently, there are no specific therapeutics approved by the FDA to treat people with COVID-19. Hydroxychloroquine is FDA-approved to prevent and treat malaria, as well as to treat the autoimmune diseases rheumatoid arthritis and lupus. Some preliminary reports have suggested that hydroxychloroquine, alone or in combination with the FDA-approved antibiotic azithromycin, may benefit people with COVID-19. Numerous clinical trials are planned or underway, including a recently launched study supported by NIH's National Heart, Lung and Blood Institute evaluating the safety and effectiveness of hydroxychloroquine for treatment of adults hospitalized with COVID-19. On March 28, the FDA issued an Emergency Use Authorization (EUA) to allow hydroxychloroquine and medical-grade chloroquine to be distributed from the Strategic National Stockpile and prescribed by doctors to hospitalized adolescents and adults with COVID-19, as appropriate, when a clinical trial is not available or feasible.
Participants in the current study, called A5395, will receive oral medications to take at home. Those randomly assigned to the experimental treatment group will take 400 mg of hydroxychloroquine twice on the first day and 200 mg twice daily for an additional six days. They also will take 500 mg of azithromycin on the first day and 250 mg daily for an additional four days. The control group will receive equivalent numbers of placebo pills. Neither the participants nor the study team will know who received experimental treatment or placebo until the end of the trial.
Participants will record their symptoms, adherence to treatment, and major events such as hospitalizations in a diary for 20 days. Study staff will follow up with participants by telephone during this period. When possible, participants will come to the clinical research site for an in-person visit at day 20. Additional follow-ups will be conducted by telephone three and six months after treatment starts.
The main objective of the study is to determine whether hydroxychloroquine and azithromycin can prevent hospitalization and death due to COVID-19. Additionally, investigators will evaluate the safety and tolerability of the experimental treatment for people with SARS-CoV-2 infection. While hydroxychloroquine and azithromycin are both considered safe in most people, they can cause side effects ranging from headache and nausea to, rarely, heart rhythm problems that can be life-threatening. Because of the risk of heart problems when hydroxychloroquine is used alone or combined with azithromycin, FDA cautions that use of hydroxychloroquine for COVID-19 should be limited to clinical trials or for treating certain hospitalized patients under EUA so clinicians can monitor patients for adverse effects.
"This study will provide key data to aid responses to the COVID-19 pandemic," said ACTG chair Judith Currier, MD, of the University of California, Los Angeles. "We are pleased to be able to leverage ACTG's existing infrastructure for HIV treatment clinical trials to quickly implement this important study."
The trial is expected to enroll quickly given the high incidence of COVID-19, and initial results may be available later this year.
Previous articleObese Mice Fed Alcohol Addiction Therapy Shed Weight and Show Improved Metabolic Function
Next articleProtein Nanowire Sensor May Have Potential Applications in Biomedicine and Healthcare
Julianna LeMieux, PhD
RELATED CONTENTMORE FROM AUTHOR
COVID-19 More Lethal If Venom-Like Enzyme Circulates at High Levels
Seven Up-and-Coming COVID-19 Drugs


text:
Star Media is all set to launch first homegrown Asian-exclusive OTT platform 11 November 2016
STAR Media Group is all set to launch its first home grown over-the-top (OTT) service called Dimsum this week. The company will offer subscription video on demand services from their curated library of the best Asian content, sourced from all over the region.
The content will mainly be drama series from Thailand, South Korea, Taiwan, Japan, China, Singapore and Malaysia. The service will be charged a flat rate fee of RM15 per month, which will allow up to 5 concurrent users and devices.
OTT China over-the-top japan asia singapore Taiwan Malaysia Thailand South Korea STAR Media Group Dimsum
Video Streaming: Key to Customer Loyalty
Indian Telco Airtel Digital TV launches SVOD service in Bengali
Apple Music Overtakes Spotify in terms of Paid US Subscribers


text:
Justia Patents Polymerizing In The Presence Of A Specified Material Other Than A ReactantUS Patent for Carbon nanotube compound and method for producing the same Patent (Patent # 7,923,527)
Carbon nanotube compound and method for producing the same
Oct 14, 2009 - Chung-Shan Institute of Science and Technology Armaments Bureau, Ministry of National Defense
The invention provides a carbon nanotube compound and method for producing the same. The method of the invention comprises the following steps. Firstly, Aniline-trimer and DMAc(dimethyl acetamide) solution are mixed to form a first solution. Secondly, Dianhydride and DMAc solution are mixed to form a second solution. The first solution and the second are mixed to form a third solution. Additionally, carboxyl-multiwall carbon nanotubes (c-MWNT), Diaminodiphenylether and DMAc solution are mixed to form a fourth solution. The third solution and the fourth are mixed to form a polyamic acid/CNT solution. Some polyamic acid/CNT solution is spread on a substrate and processed by a thermal treatment, and a carbon nanotube compound is eventually produced.
Latest Chung-Shan Institute of Science and Technology Armaments Bureau, Ministry of National Defense Patents:
Inverter System for Energy-Storing Microgrid and Controlling Method Thereof
Bridged bis(alkoxysilane) or silsesquioxane compound having benzoxazine-containing group
Method of fabricating highly cross-linked polymer spheres having uniform granular sizes
Method For Preparing Scandium-Doped Hafnium Oxide Film
Method for hot isostatic pressing a substrate
The invention relates to a carbon nanotube compound, and particularly, the invention relates to a compound having carboxylic-multiwall carbon nanotubes (c-MWNTs).
2. Description of the Prior Art
Because of the development of high technology, the influence of the electromagnetic wave to the instrument and the human body is deeply concerned.
The casing of the electronic device nowadays is mostly made of plastics having the characteristics such as light weight, low cost, easy design, and isolation, so that the static electricity is easily charged and the noise could not be eliminated causing huge influences to the instrument, the environment, and the human body. Many countries have announced the standard for the electromagnetic compatibility and the device which does not conform to the standard is not allowed to be sold. Therefore, the skill for the electromagnetic compatibility and the shielding material becomes the key point of the design of the electronic product. Because of the superior electric conductivity and the dielectric feather, the conductive polymer is emphasized in the application of the electric shielding materials.
Therefore, the invention provides a method for producing a carbon nanotube compound, which has anti-electromagnetic-radiation effect, provided as a shielding material for electric product.
A scope of the invention is to provide a method for producing a carbon nanotube compound.
According to an embodiment of the invention, the method for producing the carbon nanotube compound includes the following steps. Firstly, an Aniline-trimer and a first DMAc(dimethyl acetamide) solution are mixed to form a first solution. And then, a Dianhydride and a second DMAc solution are mixed to form a second solution. And then, the second solution and the first solution are mixed to form a third solution. Afterwards, carboxyl-multiwall carbon nanotubes (c-MWNTs), a Diaminodiphenylether, and a third DMAc solution are mixed to form a fourth solution.
Furthermore, the fourth solution and the third solution are mixed to obtain a polyamic acid/CNT solution. Finally, a part of the polyamic acid/CNT solution is spread on a substrate and then the part of the polyamic acid/CNT solution spread on the substrate is processed by a thermal treatment to form the carbon nanotube compound on the substrate.
Another scope of the invention is to provide a carbon nanotube compound, and the carbon nanotube compound could be a polyamic acid/CNT compound.
According to another embodiment of the invention, the carbon nanotube compound includes a polyamic acid and a plurality of carboxyl-multiwall carbon nanotubes distributed in the polyamic acid uniformly.
Because carbon nanotubes have weak van der waals forces to easily gathering and there is no interactive force between carbon nanotubes and polymer materials, carbon nanotubes could not be distributed in polymer materials. Compared to the prior art, the advantage of the invention is to bring carbon nanotube a dissolving character for being distributed in the polymer uniformly through a surface functional group transformation to generate a carboxylic acid (—COOH) on the surface of the carbon nanotube.
The advantage and spirit of the invention may be understood by the following recitations together with the appended drawings.
BRIEF DESCRIPTION OF THE APPENDED DRAWINGS
FIG. 1 is a flow chart illustrating the method for producing a carbon nanotube compound according to an embodiment of the invention.
FIG. 2 is a flow chart illustrating the method for producing the Aniline-trimer in FIG. 1.
The invention is to provide a method for producing a carbon nanotube compound, and the carbon nanotube compound could be a polyamic acid/CNT compound, wherein the carbon nanotubes could be carboxylic-multiwall carbon nanotubes distributed in the polyamic acid uniformly. The embodiments of the invention are described as the following.
Please refer to FIG. 1. FIG. 1 is a flow chart illustrating the method according to an embodiment of the invention.
As shown in FIG. 1, the method of the embodiment includes the following steps: firstly, in step S110 of the method, an Aniline-trimer and a first DMAc(dimethyl acetamide) solution are mixed to form a first solution. And then, in step S112 of the method, a Dianhydride and a second DMAc solution are mixed to form a second solution. And then, in step S114 of the method, the second solution and the first solution are mixed to form a third solution. Afterwards, in step S116 of the method, carboxyl-multiwall carbon nanotubes (c-MWNTs), a Diaminodiphenylether, and a third DMAc solution are mixed to form a fourth solution. In practice, the ratio of the components of the fourth solution could be adjusted according to conditions.
Furthermore, in step S118 of the method, the fourth solution and the third solution are mixed to obtain a polyamic acid/CNT solution. Finally, in step S120 of the method, a part of the polyamic acid/CNT solution is spread on a substrate and then the part of the polyamic acid/CNT solution spread on the substrate is processed by a thermal treatment to form the carbon nanotube compound on the substrate.
The conditions for executing the method of the invention will be described in the following. It should be noted that the process, the materials, the parameter, and the data are for explaining but not limiting the invention.
Firstly, 0.1363 g (0.47 mmole) Aniline-trimer is dissolved in 6 g DMAc(dimethyl acetamide) and the mixture is stirred at room temperature for 24 hours to form a first solution. Secondly, 0.5205 g (1 mmole) Dianhydride is dissolved in 1.5 g DMAc and the mixture is stirred at room temperature for 30 minutes to form a second solution. Thirdly, the second solution is mixed with the first solution and the mixture is stirred at room temperature for 24 hours to form a third solution. Fourthly, carboxyl-multiwall carbon nanotubes (c-MWNTs) and 0.2002 g (1 mmole) Diaminodiphenylether are dissolved in 2.5 g DMAc and the mixture is stirred at room temperature for 24 hours to form a fourth solution, wherein the carboxyl-multiwall carbon nanotubes occupy 0.5˜3 weight percents of the fourth solution.
Furthermore, the fourth solution is mixed with the third solution, and the mixed solution is stirred at room temperature for 24 hours to obtain a polyamic acid/CNT solution. Finally, a suitable quantity of the polyamic acid/CNT solution is spread on a glass plate and the part of the polyamic acid/CNT solution spread on the glass plate is processed by a thermal treatment to form the carbon nanotube compound on the glass plate.
The temperature of the processes of the thermal treatment is increased from room temperature to 300° C. stage by stage, and then decreased from 300° C. to room temperature stage by stage. The details of the processes of the thermal treatment for forming the carbon nanotube compound are shown in Table. 1.
TABLE 1 process temperature time
increasing Room temp.~° C. 30 min increasing 80° C.~150° C. 6 hrs increasing 150° C.~200° C. 6 hrs increasing 200° C.~250° C. 2 hrs increasing 250° C.~300° C. 3 hrs holding 300° C. 3 hrs decreasing 300° C.~Room temp. 8 hrs
In this embodiment, the carbon nanotube compound is a polyamic acid/CNT compound, wherein the carbon nanotubes are carboxylic-multiwall carbon nanotubes and distributed in the polyamic acid. Besides, a molar ratio of the Aniline-trimer to the Dianhydride to the Diaminodiphenylether is about, but not limited to, 0.47:1:1. In practice, the c-MWNTs occupy about 0.5˜3 weight percents of the fourth solution.
In practice, the c-MWNTs could be made by the following steps. Multiwall carbon nanotubes and a sulfuric acid/nitric acid mixed solution are mixed to perform a surface functional group transformation under ultrasonic vibration conditions to obtain the c-MWNTs, wherein a carboxylation is acting to generate carboxylic acids on the surfaces of the multiwall carbon nanotubes when the multiwall carbon nanotubes are mixed with the sulfuric acid/nitric acid. The ratio of the sulfuric acid to the nitric acid of the sulfuric acid/nitric acid mixed solution could be 3:1, the purity of the sulfuric acid could be 90%, and the purity of the nitric acid could be 70%. In practice, it should be noted that the ratio and the purity of the sulfuric acid to the nitric acid could be adjusted according to conditions.
The conditions for the method to produce Aniline-trimer will be described in the following. It should be noted that the process, the materials, the parameter, and the data are for explaining but not limiting the invention.
Firstly, multiwall carbon nanotubes are mixed with a sulfuric acid/nitric acid mixed solution to perform a surface functional group transformation at a temperature of 20±5° C. under ultrasonic vibration conditions for 23 hours, wherein the ratio of the sulfuric acid to the nitric acid of the sulfuric acid/nitric acid mixed solution is 3:1, the purity of the sulfuric acid is 90%, and the purity of the nitric acid is 70%. The product from the above processes is filtered in air pumping condition and then is washed by deionized water and methanol for four times. The filtered c-MWNTs are placed in air oven at a temperature of 60° C. for 24 hours to remove the unnecessary water to obtain the c-MWNT.
Please refer to FIG. 2. FIG. 2 is a flow chart illustrating the method for producing the Aniline-trimer in FIG. 1. Firstly, in step S510 of the method, a p-Phenylenediamine, a chloride solution, and an ethanol solution are mixed to form a first mixed solution. Secondly, in step S512 of the method, an ammonium persulfate and the first mixed solution are mixed to form a second mixed solution, and the second mixed solution is continuously stirred. Thirdly, in step S514 of the method, an aniline monomer is mixed with the second mixed solution to form a third mixed solution, and the third mixed solution is continuously stirred. Fourthly, in step S516 of the method, the third mixed solution is filtered in low pressure condition to obtain a first product. Fifthly, in step S518 of the method, the first product is mixed with an ammonium hydroxide solution to form a fourth mixed solution, and the fourth mixed solution is continuously stirred. Furthermore, in step S520 of the method, the fourth mixed solution is filtered in low pressure condition to obtain a second product. Finally, in step S522 of the method, the second product is purified by column chromatography to obtain the Aniline-trimer.
Firstly, 0.86 g (8 mmol) p-Phenylenediamine, 100 ml chloride solution (1M), and 40 ml ethanol solution are mixed with each other, and the mixed solution reacts in an ice bath at −5° C. to form a first mixed solution. Secondly, 1.8 g (8 mmol) ammonium persulfate is mixed with the first mixed solution to form a second mixed solution, and the second mixed solution is continuously stirred. After 5 minutes, when the product becomes brown, 1.5 ml (16 mmol) aniline monomer is mixed with the second mixed solution above-mentioned to form a third mixed solution, and the third mixed solution is continuously stirred. After several minutes, when the product becomes blue, the third mixed solution is stirred for 30 minutes.
Afterwards, the product in the filtered in the air pumping condition and then by 30 ml hydrogen chloride (1M) and 80 ml distilled water solution to obtain a first product. The first product is mixed with 40 ml ammonium hydroxide (1M) to form a fourth mixed solution, and the fourth mixed solution is stirred for 1˜2 hours at room temperature. Furthermore, the fourth mixed solution is filtered in air pumping condition and then the product is washed by the distilled water until that the pH value of the product is close to 7 to obtain a second product, wherein the second product is blue-russet. Finally, the second product is purified by column chromatography to obtain the Aniline-trimer.
Because carbon nanotubes have weak van der waals forces to easily gathering and there no interactive force between carbon nanotubes and polymer materials, carbon nanotubes could not be distributed in polymer materials uniformly. Compared to the prior art, the advantage of the invention is to bring carbon nanotube a dissolving character for being distributed in polymer uniformly through a surface functional group transformation to generate a carboxylic acid (—COOH) on the surface of the carbon nanotube.
With the example and explanations above, the features and spirits of the invention will be hopefully well described. Those skilled in the art will readily observe that numerous modifications and alterations of the invention may be made while retaining the teaching of the invention. Accordingly, the above disclosure should be construed as limited only by the metes and bounds of the appended claims.
1. A method for producing a carbon nanotube (CNT) compound, comprising the following steps:
mixing an Aniline-trimer and a first DMAc(dimethyl acetamide) solution to form a first solution;
mixing a Dianhydride and a second DMAc solution to form a second solution;
mixing the second solution and the first solution to form a third solution;
mixing carboxyl-multiwall carbon nanotubes (c-MWNTs), a Diaminodiphenylether, and a third DMAc solution to form a fourth solution;
mixing the fourth solution and the third solution to obtain a polyamic acid/CNT solution; and
spreading a part of the polyamic acid/CNT solution on a substrate and processing the part of the polyamic acid/CNT solution spread on the substrate by a thermal treatment to form the carbon nanotube compound on the substrate.
2. The method of claim 1, wherein a molar ratio of the Aniline-trimer to the Dianhydride to the Diaminodiphenylether is about 0.47:1:1.
3. The method of claim 1, wherein the c-MWNTs substantially occupy 0.5-3 weight percents of the fourth solution.
4. The method of claim 1, wherein a temperature of the thermal treatment is increased from room temperature to about 300° C. stage by stage.
5. The method of claim 1, further comprising the following step:
mixing a multiwall carbon nanotube and a sulfuric acid/nitric acid mixed solution to perform a surface functional group transformation to generate a carboxylic acid on the surface of the multiwall carbon nanotube to obtain the carboxyl-multiwall carbon nanotube.
6. The method of claim 5, wherein a volumetric ratio of the sulfuric acid to the nitric acid of the sulfuric acid/nitric acid mixed solution is 3:1; the purity of the sulfuric acid is 90%, and the purity of the nitric acid is 70%.
7. The method of claim 5, wherein the surface functional group transformation is performed under ultrasonic vibration conditions.
8. The method of claim 1, further comprising the following steps:
mixing p-Phenylenediamine, chloride solution, and ethanol solution to form first mixed solution;
mixing ammonium persulfate and the first mixed solution to form second mixed solution, and stirring the second mixed solution;
mixing an aniline monomer and the second mixed solution to form a third mixed solution and stirring the third mixed solution;
filtering the third mixed solution under low pressure condition to obtain a first product;
mixing the first product and an ammonium hydroxide solution to form a fourth mixed solution and stirring the fourth mixed solution;
filtering the fourth mixed solution under low pressure condition to obtain a second product; and
purifying the second product by column chromatography to obtain the Aniline-trimer.
9. The method of claim 8, wherein a molar ratio of the p-Phenylenediamine to the ammonium persulfate to the aniline monomer is about 1:1:2.
7273661 September 25, 2007 Moriyama et al.
20100279095 November 4, 2010 Li et al.
Wei et al. ANTEC, Soc. Plast. Eng., vol. 55(II), pp. 1369-1372, 1997.
Filed: Oct 14, 2009
Date of Patent: Apr 12, 2011
Assignee: Chung-Shan Institute of Science and Technology Armaments Bureau, Ministry of National Defense (Taoyuan County)
Inventors: Cheng-Chien Yang (Longtan Township, Taoyuan County), Jui-Ming Yeh (Zhongli), Chia-Shiang Yang (Gongguan Township, Miaoli County), Yuen-Hsin Peng (Longtan Township, Taoyuan County), Kuan-Yeh Huang (Zhongli)
Primary Examiner: David Wu
Assistant Examiner: Vu A Nguyen
Application Number: 12/579,007
Current U.S. Class: Polymerizing In The Presence Of A Specified Material Other Than A Reactant (528/351); From Carboxylic Acid Having Three Or More Carboxylic Acid Groups Or Derivatives Thereof, And An Organic Amine, Or From An Organic Amine Salt Of A Tri-or Higher Carboxylic Acid (528/350); Carboxylic Acid Contains At Least Four Carboxylic Acid Groups Or Is A Derivative Of A Carboxylic Acid Containing At Least Four Carboxylic Groups (528/353); Elemental Carbon Containing (252/502); With Organic Component (252/510); Resin, Rubber, Or Derivative Thereof Containing (252/511)
International Classification: C08G 69/28 (20060101);


text:
Filter by: Type of content
(-) Content
Course in Paris
52 results Tab to navigate through results
Research Seminar Series: Theory in Crisis
This seminar series focuses on work that responds to the urgency of the present and attempts to map unfamiliar terrain generated by the capitalist crisis.
Site: University of London Institute in Paris / Content
10 reasons to study with us in Paris
Discover what makes the University of London Institute in Paris unique, and why you should study with us.
2021 Applicant Open Day
The University of London Institute in Paris (ULIP) is an integral part of the University of London situated in the heart of Paris.
Accommodation in Paris
Get help practical advice on accommodation options for the University of London Institute in Paris.
The Admissions Policy for University of London Institute in Paris follows those of the University of London and Queen Mary University of London.
As a graduate of University of London Institute In Paris (ULIP) you will have access to all University of London alumni services.
This Global Fellowship aims to build experientially embedded research that reflects and informs the ways Paris and London are both distinct and connected.
Brexit – FAQs
Find answers to some common questions on how Brexit affects the University of London Institute in Paris.
Access the largest University careers service in Europe through the Careers Group.


The new PUBG update was made live on the test servers last week.
The newest update of PUBG which has been numbered 27 is now live on the main PC server. The new update brings a bit of everything that players wanted. The new update brings more loot on Erangel which has been one of the things that players wanted for the longest time, Flare Gun balances after the permanent introduction, buff to the M16A4 which makes it a more powerful weapon, a new weapon MP5K, and a new Survivor Pass 3: Wild Card with the new season. The new update wasmade live by PUBG Corp. on the test servers last week and is now playable right on the main PC servers.
The new weapon MP5K is a sub-machine gun chambered for 9mm ammunition which will be exclusive to Vikendi and will replace the Vector on that map. While the firing mechanics of the MP5K are similar to those of the Vector, it boasts a higher per bullet damage, but with a lower overall firing rate and DPS. This SMG also has a higher magazine capacity than the Vector, starting at 30 rounds by default with 40 rounds in an extended magazine.
PC Update 27 is now live, bringing you improved weapon balance, bug fixes, Survivor Pass 3, the MP5k and more!
The new Survivor Pass 3: Wild Card includes over 60 rewards which can be obtained within the 10 week pass duration. The new pass includes improved missions which will test players skills, an in-game feature which will provide tracking of missions in real-time and even new background music and lobby. Survivor Pass 3: Wild Card will run for 10 weeks from March 26 to June 4 and is set to cost $9.99.
There has been some heavy weapons balancing done in the new update which includes a buff to the M16A4 which now has decreased recoil, increased damage range and new attachments. changes have been made to the Vector, UMP45 and MK47 Mutant as well. The overall item spawn rates on Erangel has also been increased. On an average the loot spawn on Erangel has been increased for ARs by 12 percent, DMRs by 16 percent and SMGs by 14 percent. There have been balance changes to flare guns as well and the frequency and the loot from them have been decreased. Besides these there have been a lot of other balances and additions. Check them all out on the link in the tweet.


text:
Endorsement For The Democratic Primary For Congressional District 5: Jamie McLeod-Skinner
In recent years, Schrader has been reliable only as an obstructionist. He voted against COVID stimulus checks because he wanted more means testing. He held up Biden's infrastructure package because he didn't want to let Medicare negotiate prescription drug prices. On a conference call with Democratic leadership, he complained that the second impeachment of President Donald Trump would be "a lynching."
Source Weekly
"Our new "community of interest" stretched from Clackamas County to Sunriver and has the potential to lead to absentee governing from a Willamette Valley rep too indifferent to show up in Central Oregon. Kurt Schrader is this nightmare come to life.
Even with the advent of Zoom endorsements and debates, Schrader cannot be bothered with the primary. He went so far as to turn down time in front of the City Club of Central Oregon and the League of Women Voters, relying on mail bombardment as a brand-building technique. If Schrader is not interested in women voters in this day and age, we're not sure where his priorities lie.
Thankfully voters have a thoughtful and passionate candidate who currently resides in Central Oregon and is passionate about representing the district—the whole district. One of the qualities that strikes anyone fortunate enough to spend time discussing the issues with McLeod-Skinner is her voluminous understanding of the concerns facing constituents. We were impressed with her willingness to stand up against the uneven pressure large pharmaceutical companies are exerting on the health care system, her personal involvement in environmental issues—particularly wildfire prevention and recovery, and support for rental assistance.
….. Jamie McLeod-Skinner deserves your vote."
ICYMI: National eyes on OR-5: WSJ, NYT, Roll Call, Cook & New Republic on McLeod-Skinner's growing momentum
Cook Political Report: Electability Argument Falling Flat in 2022
"In Oregon, Democratic Rep. Kurt Schrader is facing an existential primary threat… insiders we talk to believe Schrader is in genuine danger of losing the primary."
Wall Street Journal: Oregon Voters, Angry Over Crime and Inflation, Create Tough Race for Rep. Kurt Schrader
"Mr. Schrader must make it through a May 17 primary where he is being challenged from his left over not doing more to move the Democratic agenda through Congress… interviews with more than two dozen voters in the district also show an electorate eager for change."
Cook Political Report: May Massacre? Primary Alarm Bells for Multiple House Incumbents
"According to multiple sources familiar with new polling data, Blue Dog Reps. Kurt Schrader (OR-05) and Henry Cuellar (TX-28) are now trailing progressive opponents…In OR-05, local school board member and progressive activist Jamie McLeod Skinner has the late momentum against the seven-term Schrader."
Roll Call: Multiple threats mean there's no shortage of vulnerable House members
"With less than six months to go until Election Day, the 10 most vulnerable House members face different threats… Schrader's biggest vulnerability stems from a challenge in the May 17 primary from fellow Democrat Jamie McLeod-Skinner, an attorney and emergency response coordinator."
New York Times: In an Uphill Year, Democrats of All Stripes Worry About Electability
"Ms. McLeod-Skinner has amassed considerable support from local institutions… everal county Democratic Party organizations in Oregon, ordinarily expected to back the incumbent or remain neutral, endorsed Ms. McLeod-Skinner and urged the House Democratic campaign arm, which is supporting Mr. Schrader, to stay out of the primary."
"The seven-term congressman has a serious primary challenger—possibly the most serious he's ever had as an incumbent… despite Schrader's money, name recognition, and national support."
Progressives find a new takedown target in the House
POLITICO: March 22 2022
Now top liberal groups and figures including Sen. Elizabeth Warren (Mass.), the Working Families Party and Indivisible are looking to oust the 13-year incumbent from Congress. They've lined up behind Jamie McLeod-Skinner, a school board member from central Oregon who's challenging Schrader from the left, in what could become the next marquee Democratic House primary to watch.
Several unions now favor McLeod-Skinner in challenge to Kurt Schrader
nwLaborPress: March 2, 2022
United Food and Commercial Workers Local 555, which represents 24,000 grocery and other workers, was the first to endorse Jamie McLeod-Skinner's campaign for Congress. Now Oregon Education Association (OEA), the 41,000-member teachers union, is also supporting her campaign, after a truly overwhelming 93% vote by delegates to the union's political action committee.


text:
Der Malta International Airport (IATA-Code MLA, ICAO-Code LMML) ist der einzige internationale Flughafen des Staates Malta. Er liegt in der Nähe des Ortes Luqa und ist Heimatbasis und Drehkreuz von Air Malta sowie seit 2010 eine Basis von Ryanair.

Geschichte
Die Geschichte des Flughafens reicht bis zu den ersten Jahrzehnten des 20. Jahrhunderts zurück. Die ersten Flugplätze auf Malta waren aufgrund der strategisch wichtigen Lage der Insel militärischer Art; aber schon in den 1920er Jahren erfolgten erste Zivilflüge.

Der später mehrfach umgebaute und erweiterte Flughafen war während des Zweiten Weltkrieges ein wichtiger britischer Militärflugplatz. Die Royal Air Force Station Luqa, kurz RAF Luqa beherbergte das Hauptquartier des Mediterranean Command (Mittelmeer-Kommandos). Sie erlangte insbesondere während der Belagerung Maltas durch die Achsenmächte von 1941 bis 1943 strategische Bedeutung für die Alliierten bei den Kämpfen um die Seeherrschaft im Mittelmeer und in Nordafrika. Neben Luqa als Hauptbasis gab es weitere kleinere RAF-Stationen in Ta'Qali und Ħal-Far, letztere war der erste Flugplatz Maltas, der 1929 als Marineflieger-Stützpunkt HMS Falcon der Royal Navy eröffnet worden war. Darüber hinaus gab es Nebenflugplätze bei Safi, Qrendi und auf Gozo.

Nach dem Krieg erlangte RAF Luqa vorübergehend 1956 während der Suezkrise strategische Bedeutung für die Briten. In den letzten Jahrzehnten unter britischem Kommando hatte die RAF hier Seefernaufklärer der Typen Shackleton und Nimrod stationiert. Nach der Unabhängigkeit vom Vereinigten Königreich im Jahr 1974 und dem Rückzug der Royal Air Force wurde der Flughafen 1979 den lokalen Behörden übergeben.

Bereits zu RAF-Zeiten begann die zivile Mitbenutzung. Am 31. März 1958 wurde hierzu das erste Passagierterminal eröffnet und im Oktober 1977 kam eine neue Landebahn hinzu. Ab 1987 wurde ein neues Terminal geplant und 1992 eröffnet.  In dessen Untergeschoss befindet sich die römisch-katholische Flughafenkapelle Sidtna tal-Mitjar - Our Lady of the Airways, wo bis zu drei Heilige Messen täglich stattfinden.

Betreiber und Abfertigungsgesellschaften
Flughafenbetreiber ist die börsennotierte Malta International Airport plc. (MIA), an der neben dem maltesischen Staat seit 2002 auch die Flughafen Wien AG beteiligt ist.

An Abfertigungsgesellschaften sind vertreten Air Malta als Selbstabfertiger und Drittabfertiger für einige andere Fluggesellschaften sowie die Aviaserve Ltd. für weitere Fluggesellschaften.

Lufthansa Technik Malta
Die im Jahr 2002 als Joint Venture von Air Malta und Lufthansa Technik gegründete Lufthansa Technik Malta führt MRO-Dienstleistungen (Maintenance, Repair and Overhaul – Wartung, Reparatur und Überholung) von Flugzeugen durch. Das Unternehmen beschäftigt 600 Mitarbeiter und hat im April 2009 am Flughafen Malta zwei neue Hangars für die Betreuung von Airbus-Großraumflugzeug in Betrieb genommen. Neben der Airbus-A320-Familie können derzeit auch Flugzeuge der Typen Airbus A330, Airbus A340 sowie Airbus A350 gewartet werden.

Fluggesellschaften und Ziele
Der Malta International Airport wird von insgesamt 21 Fluggesellschaften regelmäßig angeflogen. Ryanair beförderte im Jahr 2021 die meisten Passagiere, gefolgt vom Flag Carrier Air Malta.

Es werden Flüge zu 98 verschiedenen Zielen angeboten. Ein Großteil der Ziele liegt in Europa, daneben werden auch Ziele in Nordafrika und Vorderasien bedient. Die wichtigsten Länder waren im Jahr 2021 Italien und das Vereinigte Königreich.

Verkehrszahlen

Zwischenfälle
 Am 24. Oktober 1945 ging die Triebwerksleistung einer Douglas DC-3/C-47A-50-DL der British Overseas Airways Corporation (BOAC) (Luftfahrzeugkennzeichen G-AGHR) beim Start vom Flughafen Malta-Luqa zurück. Das Flugzeug geriet ins Schleudern, prallte auf einen Grat und fing Feuer. Die Maschine wurde irreparabel beschädigt. Alle Insassen überlebten den Unfall.

 Am 14. August 1946 fiel an einer Douglas DC-3/C-47A-50-DL der British Overseas Airways Corporation (BOAC) (G-AGHT) kurz nach dem Start vom Flughafen Malta-Luqa das Triebwerk Nr. 1 (links) aus. Bei der Rückkehr verlor auch  das Triebwerk Nr. 2 (rechts) im Endanflug an Leistung. Der Kapitän versuchte, die Landebahn durch eine Steilkurve noch zu erreichen. Das Flugzeug schlug hart auf, sprang wieder hoch, rutschte dann weiter, fing Feuer und brannte aus. Die Triebwerke waren wegen fehlender Treibstoffzufuhr ausgefallen, da der Tankwahlschalter versehentlich auf den fast leeren Reservetank gedreht worden war. Von den fünf Insassen des Frachtfluges wurde einer getötet.

 Am 2. Dezember 1946 setzte eine Avro York C.1 der Royal Air Force (MW268) am Flughafen Malta-Luqa vor der Landebahn auf und wurde irreparabel beschädigt. Alle Insassen überlebten.

 Am 23. Dezember 1946 wurde eine Douglas DC-3/C-47B-1-DK der British Overseas Airways Corporation (BOAC) (G-AGKD) auf dem Flughafen Malta-Luqa aus unbekannten Gründen irreparabel beschädigt. Über Personenschäden ist nichts bekannt.

 Am 24. Mai 1947 geriet eine Avro York C.1 der Royal Air Force (MW190) beim Anflug auf den Flughafen Malta-Luqa in eine Fallbö, setzte vor der Landebahn auf und wurde irreparabel beschädigt. Alle Insassen überlebten den Unfall.

 Am 13. April 1954 verunglückte eine Avro York C.1 der Scottish Airlines (G-AMUM) auf dem Flughafen Malta-Luqa. Der Anlasser eines der Triebwerke war defekt. Deshalb kam der Kapitän auf die Idee, dieses Triebwerk anzulassen, indem der Propeller durch Fahrtwind beim Rollen beschleunigt werden sollte. Dies gelang tatsächlich, aber erst so kurz vor dem Ende der Startbahn, dass dieses zügig überrollt und das Flugzeug irreparabel beschädigt wurde. Alle 3 Besatzungsmitglieder überlebten das Missgeschick.

 Am 18. Februar 1956 stürzte die Avro York G-ANSY der Scottish Airlines kurz nach dem Start vom Flughafen Malta nach einem Triebwerksschaden ab. Alle 50 Personen an Bord kamen ums Leben.

 Am 20. Mai 1958 setzte eine Avro York C.1 der britischen Dan-Air (G-AMUT) bei der Landung auf dem Flughafen Malta spät auf und überrollte das Landebahnende. Um das Flugzeug zum Stehen zu bringen wurde das Fahrwerk eingefahren. Die Maschine kollidierte mit einer Mauer und wurde irreparabel beschädigt. Alle drei Besatzungsmitglieder des Frachtflugs überlebten.

 Am 5. Januar 1960 fiel bei einer Vickers Viscount 701 der British European Airways (BEA) (G-AMNY) nach dem Aufsetzen am Zielflughafen Malta das Hydrauliksystem und damit die Bremsen und die Bugradsteuerung aus. Auf dem abschüssigen Gelände rollte die Maschine gegen den Kontrollturm. Keiner der 51 Insassen kam zu Schaden, das Flugzeug war allerdings schrottreif.

 Am 23. November 1985 landete die entführte Boeing 737-266 SU-AYH der Egyptair. Nachdem die Terroristen am Flughafen Malta bereits zwei Geiseln erschossen hatten, starben bei der Erstürmung weitere 58 Menschen. Die Maschine wurde zerstört (siehe auch Egypt-Air-Flug 648).

 Am 24. Oktober 2016 stürzte eine Fairchild Swearingen Metro (N577MX) kurz nach dem Start ab, wobei alle fünf Menschen an Bord ums Leben kamen. Die Maschine war im Auftrag des französischen Zolls zur Kontrolle der Menschenschmugglerroute von der libyschen Küste nach Europa eingesetzt. Die Maschine war in den USA registriert und an eine Firma in Luxemburg verleast.

Weblinks

 Offizielle Webseite des Flughafens

Einzelnachweise

Malta
Flughafen in Malta
Bauwerk in Luqa
Verkehr (Luqa)

redpajama_set_name: RedPajamaWikipedia


The Cherokee Nation tribe built the Hard Rock Hotel & Casino Tulsa in Catoosa, Oklahoma back in 2004 for an estimated $80 million. The operation was a success and the tribe decided to expand the facility in 2009 by adding a convention center and a hotel tower with expensive suites catering to VIP clientele. The cost of the expansion was estimated to be around $125 million. Now, five years later, the business arm of the Cherokee Nation tribe has agreed to spend an additional $6.9 million to renovate the casino. The renovation will start in May and will be rolled out in three phases and is expected to be completed by the end of 2015.


Our product range includes a wide range of flood light, led tube light driver, driver for led tube light and led tube light adapters.
We are a well-known manufacturer and supplier of a wide range of LED Tube Light Driver for LED Tube Light, Led Bulb & LED Strip etc.
We are a well known manufacturer and supplier of a wide range of Driver for LED Tube Light. All our products have a warranty of one year against any manufacturing defects. Clients can avail these products as per their specifications. Our range of products are manufactured using quality material and are tested on several parameters to ensure their flawlessness.
Our organization has gained immense popularity for offering a wide range of LED Tube Light Adapter. These products are developed in compliance with international quality standard and norms. Owing to their features like high efficiency, easy to install and use, these products are widely demanded by the clients. To provide the comfort and convenience to the clients, these products are also available as per the clients need and requirements.
Looking for LED Tubelight Driver ?